United Capital Financial Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.65M | Sell |
2,651
-289
| -10% | -$197K | 0.01% | 626 |
|
|
2026
Q1 | $2.27M | Sell |
2,940
-42
| -1% | -$32.2K | 0.01% | 522 |
|
|
2025
Q4 | $2.3M | Buy |
2,982
+411
| +16% | +$279K | 0.01% | 499 |
|
|
2025
Q3 | $1.45M | Buy |
2,571
+337
| +15% | +$191K | 0.01% | 540 |
|
|
2025
Q2 | $1.17M | Sell |
2,234
-122
| -5% | -$68.1K | 0.01% | 551 |
|
|
2025
Q1 | $1.49M | Sell |
2,356
-14
| -0.6% | -$9.63K | 0.01% | 481 |
|
|
2024
Q4 | $1.69M | Sell |
2,370
-631
| -21% | -$530K | 0.01% | 454 |
|
|
2024
Q3 | $3.16M | Sell |
3,001
-26
| -0.9% | -$28.9K | 0.03% | 330 |
|
|
2024
Q2 | $3.18M | Buy |
3,027
+32
| +1% | +$31K | 0.03% | 331 |
|
|
2024
Q1 | $2.88M | Sell |
2,995
-336
| -10% | -$319K | 0.02% | 362 |
|
|
2023
Q4 | $2.93M | Sell |
3,331
-1,106
| -25% | -$911K | 0.02% | 353 |
|
|
2023
Q3 | $3.65M | Sell |
4,437
-232
| -5% | -$182K | 0.02% | 343 |
|
|
2023
Q2 | $3.35M | Buy |
4,669
+74
| +2% | +$57.1K | 0.02% | 368 |
|
|
2023
Q1 | $3.78M | Buy |
4,595
+859
| +23% | +$648K | 0.02% | 355 |
|
|
2022
Q4 | $2.7M | Buy |
3,736
+2,176
| +139% | +$1.61M | 0.02% | 430 |
|
|
2022
Q3 | $1.07M | Buy |
1,560
+52
| +3% | +$32.7K | 0.01% | 597 |
|
|
2022
Q2 | $891K | Sell |
1,508
-49
| -3% | -$31.9K | ﹤0.01% | 653 |
|
|
2022
Q1 | $1.09M | Sell |
1,557
-72
| -4% | -$45.6K | 0.01% | 648 |
|
|
2021
Q4 | $1.03M | Sell |
1,629
-86
| -5% | -$52.9K | ﹤0.01% | 668 |
|
|
2021
Q3 | $1.04M | Sell |
1,715
-216
| -11% | -$134K | 0.01% | 669 |
|
|
2021
Q2 | $1.08M | Sell |
1,931
-383
| -17% | -$194K | 0.01% | 673 |
|
|
2021
Q1 | $1.09M | Sell |
2,314
-58
| -2% | -$28.2K | 0.01% | 641 |
|
|
2020
Q4 | $1.15M | Buy |
2,372
+281
| +13% | +$152K | 0.01% | 643 |
|
|
2020
Q3 | $1.17M | Buy |
2,091
+62
| +3% | +$37.6K | 0.01% | 616 |
|
|
2020
Q2 | $1.26M | Buy |
2,029
+829
| +69% | +$471K | 0.01% | 602 |
|
|
2020
Q1 | $586K | Buy |
1,200
+314
| +35% | +$130K | ﹤0.01% | 768 |
|
|
2019
Q4 | $332K | Buy |
886
+522
| +143% | +$176K | ﹤0.01% | 1103 |
|
|
2019
Q3 | $101K | Sell |
364
-589
| -62% | -$174K | ﹤0.01% | 1243 |
|
|
2019
Q2 | $298K | Buy |
953
+304
| +47% | +$101K | ﹤0.01% | 1216 |
|
|
2019
Q1 | $266K | Sell |
649
-691
| -52% | -$285K | ﹤0.01% | 1172 |
|
|
2018
Q4 | $500K | Buy |
1,340
+63
| +5% | +$23.1K | ﹤0.01% | 919 |
|
|
2018
Q3 | $516K | Buy |
1,277
+674
| +112% | +$257K | ﹤0.01% | 963 |
|
|
2018
Q2 | $208K | Sell |
603
-80
| -12% | -$25K | ﹤0.01% | 1214 |
|
|
2018
Q1 | $235K | Buy |
683
+123
| +22% | +$42.8K | ﹤0.01% | 1182 |
|
|
2017
Q4 | $214K | Sell |
560
-28
| -5% | -$11.3K | ﹤0.01% | 1217 |
|
|
2017
Q3 | $263K | Buy |
588
+107
| +22% | +$50.9K | ﹤0.01% | 1156 |
|
|
2017
Q2 | $236K | Buy |
+481
| New | +$210K | ﹤0.01% | 1154 |
|
|
2016
Q4 | – | Sell |
-576
| Closed | -$232K | – | 1308 |
|
|
2016
Q3 | $232K | Buy |
+576
| New | +$231K | ﹤0.01% | 1146 |
|
|
2015
Q4 | – | Sell |
-636
| Closed | -$296K | – | 1273 |
|
|
2015
Q3 | $296K | Buy |
636
+120
| +23% | +$64.4K | ﹤0.01% | 1061 |
|
|
2015
Q2 | $263K | Buy |
+516
| New | +$252K | ﹤0.01% | 1112 |
|
Other funds holding REGN
United Capital Financial Advisors's REGN Position: Q2 2026 in Review
United Capital Financial Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 9.8% in Q2 2026, selling an estimated $197K and leaving 2,651 shares worth $1.65M. The position accounts for 0.01% of the portfolio, ranked #626.
United Capital Financial Advisors first reported a position in REGN in Q2 2015 and has held it in 40 quarters since. The position peaked at $3.78M in Q1 2023. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- United Capital Financial Advisors held 2,651 shares of Regeneron Pharmaceuticals worth $1.65M as of Q2 2026.
- United Capital Financial Advisors sold 289 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $197K.
- Regeneron Pharmaceuticals made up 0.01% of United Capital Financial Advisors's portfolio in Q2 2026, its #626 holding.
- United Capital Financial Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2015 and has held it in 40 quarters since.
- United Capital Financial Advisors's Regeneron Pharmaceuticals position peaked at $3.78M in Q1 2023.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on United Capital Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.